Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Muto, Satoru; Matsubara, Takeshi; Inoue, Takamitsu; Kitamura, Hiroshi; Yamamoto, Kazuhiro; Ishii, Takefumi; Yazawa, Masahiko; Yamamoto, Ryohei; Okada, Naoto; Mori, Kiyoshi; Yamada, Hitoshi; Kuwabara, Tomohiko; Yonezawa, Atsushi; Fujimaru, Takuya; Kawano, Haruna; Yokoi, Hideki; Doi, Kent; Hoshino, Junichi; Yanagita, Motoko

doi:10.1007/s10147-023-02372-4

Cited by 6 publications

(4 citation statements)

References 282 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reasons for this include risk factors specific to patients with CKD and those due to immunosuppressive drug use, in addition to risk factors similar to those in the general population (see General review 1-3: "2. Patients who have undergone renal transplantation" [1,52]). In particular, the activation of cancer-causing viruses and suppression of immune surveillance in cancerous cells by immunosuppressive drugs greatly contribute to the development of malignant tumors.…”

Section: Background and Purposementioning

confidence: 99%

“…The use of immunosuppressants is known to be an adverse prognostic factor in patients with cancer, and the number of immunosuppressants used by a renal transplant recipient is at times reduced following a cancer diagnosis to avoid exacerbation (see General Review 1-3: "2. patients who have undergone renal transplantation" [1,52]). While it may be necessary to consider the use of a triple immunosuppressant regimen when initiating ICI therapy, there are no reports available to evaluate the evidence.…”

Section: Risk Of Rejectionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Yanagita,

Muto,

Nishiyama

et al. 2023

Clin Exp Nephrol

Self Cite

View full text Add to dashboard Cite

Section: Background and Purposementioning

confidence: 99%

Section: Risk Of Rejectionmentioning

confidence: 99%

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Yanagita,

Muto,

Nishiyama

et al. 2023

Clin Exp Nephrol

Self Cite

View full text Add to dashboard Cite

“…The administration of either anti-cancer drugs, immunosuppressive medicines, or biological therapy can initiate this occurrence. CD8+ T cell exhaustion resulting from the overexpression of PD-1 is observed in persistent viral infections, such as chronic hepatitis B[ 22 , 23 ] (Figure 1 ).…”

Section: Possible Immunological Mechanisms Of Hbv Reactivationmentioning

confidence: 99%

Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies

Ma,

Yan,

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

Hepatitis B virus (HBV) reactivation is a clinically significant challenge in disease management. This review explores the immunological mechanisms underlying HBV reactivation, emphasizing disease progression and management. It delves into host immune responses and reactivation’s delicate balance, spanning innate and adaptive immunity. Viral factors’ disruption of this balance, as are interactions between viral antigens, immune cells, cytokine networks, and immune checkpoint pathways, are examined. Notably, the roles of T cells, natural killer cells, and antigen-presenting cells are discussed, highlighting their influence on disease progression. HBV reactivation’s impact on disease severity, hepatic flares, liver fibrosis progression, and hepatocellular carcinoma is detailed. Management strategies, including anti-viral and immunomodulatory approaches, are critically analyzed. The role of prophylactic anti-viral therapy during immunosuppressive treatments is explored alongside novel immunotherapeutic interventions to restore immune control and prevent reactivation. In conclusion, this comprehensive review furnishes a holistic view of the immunological mechanisms that propel HBV reactivation. With a dedicated focus on understanding its implications for disease progression and the prospects of efficient management strategies, this article contributes significantly to the knowledge base. The more profound insights into the intricate interactions between viral elements and the immune system will inform evidence-based approaches, ultimately enhancing disease management and elevating patient outcomes. The dynamic landscape of management strategies is critically scrutinized, spanning anti-viral and immunomodulatory approaches. The role of prophylactic anti-viral therapy in preventing reactivation during immunosuppressive treatments and the potential of innovative immunotherapeutic interventions to restore immune control and proactively deter reactivation.

show abstract

“…Nephrotic range proteinuria (21-64%) and hypertension (3-36%) are the two most common dose-dependent adverse effects of bevacizumab reported in the literature [ 2 , 3 ]. Studies show that a higher dose of bevacizumab (≥10 mg/kg) is associated with a higher risk of proteinuria [ 4 ]. Among the patients with nephropathy, thrombotic microangiopathy is the characteristic histologic pattern [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Bevacizumab-Induced Nephropathy Presenting as Crescentic Glomerulopathy

Onteddu,

Mudupula Vemula,

Areddy

et al. 2023

Cureus

View full text Add to dashboard Cite

Bevacizumab-induced nephropathy is a common adverse event observed in patients who receive chemotherapy. These patients usually present with hypertension and nephrotic range proteinuria. Thrombotic microangiopathy is the characteristic histologic pattern of bevacizumab-induced nephropathy. However, a few cases reported IgA vasculitis with nephritis as an unusual pattern. In this case report, we describe a patient diagnosed with bevacizumab-induced nephropathy with a distinctive histologic pattern demonstrating focal proliferative crescentic glomerulonephritis with polyclonal immune complex deposition.

show abstract

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Cited by 6 publications

References 282 publications

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies

Bevacizumab-Induced Nephropathy Presenting as Crescentic Glomerulopathy

Contact Info

Product

Resources

About